New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
06:42 EDTAMPEAmpio modifies Ampion IND to include dose escalation run-in study
Ampio Pharmaceuticals announced that it's Phase III clinical study of Ampion for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA. Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted "The company has modified the original study design to accommodate the FDA recommendations and submitted this upgraded IND study protocol for clearance to begin treating patients. A Clinical Research Organization has been engaged and multiple clinical sites have been selected that are ready to enroll patients in the study. The dose ranging run-in study will commence shortly and will include 320 patients in total comparing 4 ml to 10 ml injection using the WOMAC pain scale."
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:04 EDTAMPEAmpio subsidiary secures European distribution for RedoxSYS diagnostic system
Ampio subsidiary Luoxis Diagnostics has secured long-term agreements with European distributors Eurobio, Una Health Limited, and THP Medical, to offer Luoxis' RedoxSYS Diagnostic System to academic and pharma-based research centers within their respective territories. RedoxSYS is a diagnostic platform and robust research tool capable of measuring oxidation-reduction potential in the body in response to injury, illness, or stress. Eurobio was granted territorial rights to offer RedoxSYS to institutions based in France and Switzerland, while Una Health Limited and THP Medical were granted territorial rights to the U.K. and Austria, respectively. These are multi-year agreements with the option to renew at the 3-5 year mark.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use